Insulatard Penfill

Insulin Human, the active ingredient in Insulatard Penfill, is a insulin presented as a solution for injection (prefilled pen) for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in adults and children requiring basal insulin therapy.

GNH USA supplies Insulatard Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulatard Penfill provides basal insulin therapy for diabetes mellitus, helping to maintain stable blood glucose levels.

- Type 1 diabetes mellitus: provides long‑acting insulin to control fasting glucose. - Type 2 diabetes mellitus: supplies basal insulin to complement oral agents and improve glycaemic control. - Diabetes mellitus (general): offers consistent insulin coverage to reduce hyperglycaemia throughout the day.

Insulatard Penfill may be associated with a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Hypoglycaemia: symptoms such as sweating, tremor, dizziness, or confusion. - Injection‑site pain or erythema: mild discomfort at the injection site. - Weight gain: gradual increase in body weight with ongoing therapy. - Lipodystrophy: localized thickening or loss of subcutaneous fat at injection sites. - Edema: mild swelling of the extremities.

Serious or Rare Side Effects: - Severe hypoglycaemia: loss of consciousness or seizures requiring assistance. - Allergic reaction: urticaria, angio‑edema, or anaphylaxis. - Insulin antibody syndrome: formation of antibodies that alter insulin action. - Lipohypertrophy: large, firm masses of fatty tissue that may affect insulin absorption. - Necrotising fasciitis: extremely rare but serious infection at injection site.

When using Insulatard Penfill, several precautions should be observed to ensure safety and effectiveness. - Dose titration: adjust insulin dose based on regular blood glucose monitoring and clinical response. - Hypoglycaemia risk: educate patients to recognize early signs and have fast‑acting carbohydrate available. - Renal impairment: consider dose reduction in patients with reduced kidney function. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Drug interactions: review concomitant medications that may potentiate or diminish insulin effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulatard Penfill can interact with other medicines, influencing glucose control or masking symptoms.

Major Interactions (Avoid): - Sulfonylureas: combined use markedly increases risk of severe hypoglycaemia. - Beta‑blockers: may blunt typical hypoglycaemia warning signs such as tachycardia. - MAO inhibitors: unpredictable alterations in blood glucose levels may occur.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: can raise blood glucose, requiring closer monitoring. - Corticosteroids: may increase insulin requirements due to hyperglycaemic effect. - ACE inhibitors: may enhance insulin sensitivity and affect glucose control.